Cilostazol combined with P2Y12 receptor inhibitors: A substitute antiplatelet regimen for aspirin-intolerant patients undergoing percutaneous coronary stent implantation.

Abstract

BACKGROUND:

Cilostazol combined with P2Y12 receptor inhibitor has been used as a substitute regimen for aspirin-intolerant patients undergoing percutaneous coronary stent implantation on a small scale. Its exact impact on platelet functions and clinical benefits of aspirin-intolerant patients is unknown.

HYPOTHESIS:

Cilostazol combined with P2Y12 receptor inhibitors could be used as a substitute antiplatelet regimen for aspirin-intolerant patients undergoing percutaneous coronary stent implantation.

METHODS:

In this multicenter prospective cohort trial, patients undergoing elective percutaneous coronary stent implantation were assigned to the cilostazol group (cilostazol plus P2Y12 receptor inhibitors), based on aspirin intolerance criteria, or the aspirin group (aspirin plus P2Y12 receptor inhibitors). Platelet PAC-1, CD62p, and vasodilator-stimulated phosphoprotein phosphorylation (VASP-P) were detected by flow cytometry. The primary endpoints were major adverse cardiovascular and cerebrovascular events (MACCE) including all-cause death, acute myocardial infarction, emerging arrhythmia, nonfatal stroke, and heart failure. The secondary endpoints were the Bleeding Academic Research Consortium (BARC) bleeding events.

RESULTS:

One hundred and fifty-four aspirin-intolerant percutaneous coronary stent implantation patients and 154 matched aspirin-tolerant patients from a total of 2059 percutaneous coronary stent implantation patients were enrolled. The relative activation level of PAC-1, CD62p, and platelet reaction index reflected by the VASP-P test were similar in the two groups (p > .05). After 12 months of follow-up, the incidence of all-cause death was 1.9% in the cilostazol group and 1.3% in the aspirin group (risk ratio [RR], 1.500; 95% confidence interval [CI], 0.254-8.852; p = 1.000); the incidence of acute myocardial infarction was 0.6% in the cilostazol group and 1.3% in the aspirin group (RR, 0.500; 95% CI, 0.046-5.457; p = 1.000). No significant difference was seen in other MACCE events, or in any types of BARC bleeding events.

CONCLUSIONS:

Cilostazol combined with P2Y12 inhibitors was not inferior to aspirin-based standard therapy and could be used as a reasonable substitute antiplatelet regimen for aspirin-intolerant patients undergoing percutaneous coronary stent implantation, but again with limitations, which required a larger sample and longer follow-up to confirm its efficacy.

• Authors: Yikai Zhao, Peng Zhou, Wen Gao, Haoxuan Zhong, Yufei Chen, Wei Chen, Maieryemu Waresi, Kun Xie, Haiming Shi, Hui Gong, Guibin He, Zhaohui Qiu, Xinping Luo, Jian Li
• Journal: Clinical cardiology (Clin Cardiol) Vol. 45 Issue 2 Pg. 189-197 (Feb 2022) ISSN: 1932-8737 [Electronic] United States
• PMID: 35120275 (Publication Type: Journal Article, Multicenter Study)
• Copyright: © 2022 The Authors. Clinical Cardiology published by Wiley Periodicals, LLC.

Chemical References

• Platelet Aggregation Inhibitors
• Cilostazol
• Aspirin

Topics

• Aspirin (adverse effects)
• Cilostazol (adverse effects)
• Drug Therapy, Combination
• Drug-Eluting Stents
• Humans
• Percutaneous Coronary Intervention (adverse effects)
• Platelet Aggregation Inhibitors (adverse effects)
• Prospective Studies
• Stents
• Treatment Outcome